Cardiologists Urge Stronger Safeguards as Gene Editing Moves Towards Common Diseases

A new perspective published in JAMA Internal Medicine on October 28, 2026, highlights the rapid progression of genomic therapies towards treating widespread conditions such as high cholesterol, heart disease, obesity, and diabetes. Two cardiologists from the University of Michigan Health Frankel Cardiovascular Center propose strategies to ensure long-term safety, durability, and affordability, emphasizing the need for appropriate safeguards as these therapies transition from rare to common diseases.